These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15297806)

  • 41. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.
    Hooper WC; Lally C; Austin H; Renshaw M; Dilley A; Wenger NK; Phillips DJ; Whitsett C; Rawlins P; Evatt BL
    Thromb Res; 2000 Aug; 99(3):223-30. PubMed ID: 10942788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults.
    Ringelstein M; Jung A; Berger K; Stoll M; Madlener K; Klötzsch C; Schlachetzki F; Stolz E
    J Neurol; 2012 Nov; 259(11):2287-92. PubMed ID: 22527222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
    Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
    Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children.
    Haralambous E; Hibberd ML; Hermans PW; Ninis N; Nadel S; Levin M
    Crit Care Med; 2003 Dec; 31(12):2788-93. PubMed ID: 14668616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
    Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
    Błasiak J; Smolarz B
    Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.
    Grubic N; Stegnar M; Peternel P; Kaider A; Binder BR
    Thromb Res; 1996 Dec; 84(6):431-43. PubMed ID: 8987164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasminogen activator inhibitor I 4G/5G polymorphism in neonatal respiratory distress syndrome.
    Armangil D; Yurdakök M; Okur H; Gürgey A
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):352-7. PubMed ID: 20460339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin.
    Roncal C; Orbe J; Belzunce M; Rodríguez JA; Páramo JA
    J Thromb Haemost; 2006 Aug; 4(8):1798-803. PubMed ID: 16879223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children with asthma and allergic rhinitis.
    Ozbek OY; Ataç FB; Ogus E; Ozbek N
    Allergy Asthma Proc; 2009; 30(1):41-6. PubMed ID: 19063817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
    Xu F; Liu H; Sun Y
    Ren Fail; 2016; 38(1):157-62. PubMed ID: 26616527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of the plasminogen activator inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G promoter polymorphism with risk of keloid in a Chinese Han population.
    Wang Y; Long J; Wang X; Sun Y
    Med Sci Monit; 2014 Oct; 20():2069-73. PubMed ID: 25350781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The -675 4G/5G
    Anaya-Macias BU; De la Cruz-Mosso U; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla G; González-López L; Gámez-Nava JI; Pérez-Guerrero EE; Barrientos-Avalos SL; Muñoz-Valle JF
    Autoimmunity; 2020 Mar; 53(2):71-77. PubMed ID: 31829037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians.
    Lottermoser K; Düsing R; Ervens P; Koch B; Brüning T; Sachinidis A; Vetter H; Ko Y
    J Mol Med (Berl); 2001 Jun; 79(5-6):289-93. PubMed ID: 11485022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy.
    Malle EM; Posch-Pertl L; Renner W; Pinter-Hausberger S; Singer C; Haas A; Wedrich A; Weger M
    Ophthalmic Genet; 2018 Dec; 39(6):714-716. PubMed ID: 30442055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.
    Gilabert-Estellés J; Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A
    Thromb Res; 2012 Aug; 130(2):242-7. PubMed ID: 22055623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.
    Sun L; Lv H; Wei W; Zhang D; Guan Y
    J Endocrinol Invest; 2010 Feb; 33(2):77-82. PubMed ID: 19636212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.